Dette skal sammenholdes med et fald på 0, 08% hos patienter, der i stedet fik placebo som tillægsbehandling.
In combination with metformin, a daily dose of 100 mg Xelevia reduced HbA1c by 0.70% (from 7.96 to 7.26%) after 24 weeks, compared to a fall of 0.08% in the patients adding placebo.